TY - JOUR
T1 - Clinical characteristics and outcomes of benign, atypical, and malignant breast adenomyoepithelioma
T2 - a single institution's experience
AU - Wiens, Naomi
AU - Hoffman, Daniel I.
AU - Huang, Cassie Ye
AU - Nayak, Anupma
AU - Tchou, Julia
N1 - Publisher Copyright:
© 2019
PY - 2020/4
Y1 - 2020/4
N2 - Background: Breast adenomyoepithelioma (AME) is rare. We sought to evaluate clinical characteristics, treatment, and outcomes of a contemporary patient cohort stratified by histology. Methods: We queried health records containing “adenomyoepithelioma” between 2000 and 2018. Histology was confirmed with centralized review and classified into benign, atypical, and malignant. Clinical characteristics, demographics, treatment, and oncologic outcomes were compared. Results: Our query yielded 24 patients with adenomyoethelioma. Histologic diagnosis was confirmed in 12 (benign n = 6, atypical n = 3, malignant n = 3). Excision (n = 11) was the usual initial treatment, with margin status available in 10 patients. Mean follow up was 44 months (range 1–138 months) with no local recurrence observed. Two patients with benign AME presented with concurrent contralateral breast cancer, and one with malignant AME died of metastatic AME. Conclusion: Wide excision of atypical and malignant AME is recommended as local recurrence when excised completely was not observed. Given metastatic potential of malignant AME, multimodal therapy may be warranted.
AB - Background: Breast adenomyoepithelioma (AME) is rare. We sought to evaluate clinical characteristics, treatment, and outcomes of a contemporary patient cohort stratified by histology. Methods: We queried health records containing “adenomyoepithelioma” between 2000 and 2018. Histology was confirmed with centralized review and classified into benign, atypical, and malignant. Clinical characteristics, demographics, treatment, and oncologic outcomes were compared. Results: Our query yielded 24 patients with adenomyoethelioma. Histologic diagnosis was confirmed in 12 (benign n = 6, atypical n = 3, malignant n = 3). Excision (n = 11) was the usual initial treatment, with margin status available in 10 patients. Mean follow up was 44 months (range 1–138 months) with no local recurrence observed. Two patients with benign AME presented with concurrent contralateral breast cancer, and one with malignant AME died of metastatic AME. Conclusion: Wide excision of atypical and malignant AME is recommended as local recurrence when excised completely was not observed. Given metastatic potential of malignant AME, multimodal therapy may be warranted.
KW - Adenomyoepithelioma
KW - Atypical adenomyoepithelioma
KW - Benign breast disease
KW - Breast cancer
KW - Malignant adenomyoepithelioma
UR - http://www.scopus.com/inward/record.url?scp=85064061585&partnerID=8YFLogxK
U2 - 10.1016/j.amjsurg.2019.03.026
DO - 10.1016/j.amjsurg.2019.03.026
M3 - Article
C2 - 30982573
AN - SCOPUS:85064061585
SN - 0002-9610
VL - 219
SP - 651
EP - 654
JO - American Journal of Surgery
JF - American Journal of Surgery
IS - 4
ER -